Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657083 | 0.80 | GRM4 (0.38) | EGFRFGFR4GRM4CSNK2A2CSNK2B | |
| SCHEMBL24615675 | 0.80 | GRM4 (0.38) | EGFRFGFR4GRM4CSNK2A2CSNK2B | |
| SCHEMBL20666241 | 0.76 | EGFR (0.30) | EGFRFGFR4 | |
| SCHEMBL23847835 | 0.76 | CSNK2A1 (0.32) | EGFRFGFR4CYP3A4TSHR | |
| SCHEMBL10765869 | 0.71 | EGFR (0.47) | ALDH1A1EGFRRAB9AHSD17B10NPC1 | |
| SCHEMBL22966311 | 0.69 | CSNK2A2 (0.39) | ALDH1A1EGFRCSNK2A2CSNK2B | |
| SCHEMBL14660618 | 0.69 | CDC25B (0.36) | EGFR | |
| SCHEMBL29937137 | 0.68 | GRM4 (0.33) | GRM4 | |
| SCHEMBL7832234 | 0.68 | HTT (0.38) | HTTEGFRHSD17B10HPGDFGFR4 | |
| SCHEMBL4147243 | 0.67 | EGFR (0.60) | EGFRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | ALDH1A1 1195/4885HTT 4484/4885EGFR 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.